|
1）Palevsky PM, Molitoris BA, Okusa MD, et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol. 2012; 7: 844-50
|
|
|
|
2）Parikh CR, Thiessen-Philbrook H, Garg AX, et al. TRIBE-AKI Consortium: Performance of kidney injury molecule-1 and liver fatty acidbinding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol. 2013; 8: 1079-88
|
|
|
|
|
|
3）Parikh CR, Coca SG, Thiessen-Philbrook H, et al. TRIBE-AKI Consortium: Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011; 22: 1748-57
|
|
|
|
|
|
4）Parikh CR, Devarajan P, ZappitelliM, et al. TRIBE-AKI Consortium: Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol. 2011; 22: 1737-47
|
|
|
|
|
|
5）Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013; 17: R25
|
|
|
|
|
|
6）Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalinsiderophore-iron complex rescues the kidney from ischemiareperfusion injury. J Clin Invest. 2005; 115: 610-21
|
|
|
|
|
|
7）Li JY, Ram G, Gast K, et al. Detection of intracellular iron by its regulatory effect. Am J Physiol Cell Physiol. 2004; 287: C1547-59
|
|
|
|
|
|
8）Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998; 273: 4135-42
|
|
|
|
|
|
9）Ichimura T, Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008; 118: 1657-68
|
|
|
|
|
|
10）Lim AI, Chan LY, Lai KN, et al. Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells. Int J Biochem Cell Biol. 2012; 44: 1040-50
|
|
|
|
|
|
11）Melnikov VY, Ecder T, Fantuzzi G, et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest. 2001; 107: 1145-52
|
|
|
|
|
|
12）Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol. 2011; 22: 1007-18
|
|
|
|
|
|
13）Melnikov VY, Faubel S, Siegmund B, et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest. 2002; 110: 1083-91
|
|
|
|
|
|
14）Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991; 273[Pt 3]: 759-66
|
|
|
|
|
|
15）Katagiri D, Doi K, Honda K, et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg. 2012; 93: 577-83
|
|
|
|
|
|
16）Atshaves BP, McIntosh AL, Payne HR, et al. Effect of branched-chain fatty acid on lipid dynamics in mice lacking liver fatty acid binding protein gene. Am J Physiol Cell Physiol. 2005; 288: C543-58
|
|
|
|
|
|
17）Wang G, Gong Y, Anderson J, et al. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology. 2005; 42: 871-9
|
|
|
|
|
|
18）Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol. 2007; 18: 2894-902
|
|
|
|
|
|
19）Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006; 47: 439-44
|
|
|
|
|
|
20）Doi K, Negishi K, Ishizu T, et al. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med. 2011; 39: 2464-9
|
|
|
|
|
|
21）Negishi K, Noiri E, Maeda R, et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int. 2008; 73: 1374-84
|
|
|
|
|
|
22）Portilla D, Dai G, Peters JM, et al. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol. 2000; 278: F667-75
|
|
|
|
|
|
23）Kobori H, Ohashi N, Katsurada A, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens. 2008; 2: 349-54
|
|
|
|
|
|
24）Alge JL, Karakala N, Neely BA, et al. SAKInet Investigators: Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol. 2013; 8: 184-93
|
|
|
|
|
|
25）Alge JL, Karakala N, Neely BA, et al. SAKInet Investigators: Association of elevated urinary concentration of renin-angiotensin system components and severe AKI. Clin J Am Soc Nephrol. 2013; 8: 2043-52
|
|
|
|
|
|
26）Efrati S, Berman S, Hamad RA, et al. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Nephrol Dial Transplant. 2012; 27: 136-45
|
|
|
|
|
|
27）Molinas SM, Cortés-González C, González-Bobadilla Y, et al. Effects of losartan pretreatment in an experimental model of ischemic acute kidney injury. Nephron Exp Nephrol. 2009; 112: e10-9
|
|
|
|
|
|
28）Wang Z, Liu Y, Han Y, et al. Protective effects of aliskiren on ischemiareperfusion-induced renal injury in rats. Eur J Pharmacol. 2013; 718: 160-6
|
|
|
|
|
|
29）Coca SG, Garg AX, Swaminathan M, et al. TRIBE-AKI Consortium: Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant. 2013; 28: 2787-99
|
|
|
|
|
|
30）Seo DW, Kim SH, Eom SH, et al. TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res. 2008; 76: 145-51
|
|
|
|
|
|
31）Hoegy SE, Oh HR, Corcoran ML, et al. Tissue in hibitor of metalloproteinases-2 (TIMP-2) suppresses TKRgrowth factor signaling independent of metalloproteinase inhibition. J Biol Chem. 2001; 276: 3203-14
|
|
|
|
|
|
32）Barasch J, Yang J, Qiao J, et al. Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. J Clin Invest. 1999; 103: 1299-307
|
|
|
|
|
|
33）Zhu S, Xu F, Zhang J, et al. Insulin-like growth factor binding protein-related protein 1 and cancer. Clin Chim Acta. 2014; 431: 23-32
|
|
|
|
|
|
34）Aregger F, Uehlinger DE, Witowski J, et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int. 2014; 85: 909-19
|
|
|
|
|
|
35）Evdokimova V, Tognon CE, Benatar T, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal. 2012; 5: ra92
|
|
|
|
|
|
36）Ding H, Kopple JD, Cohen A, et al. Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest. 1993; 91: 2281-7
|
|
|
|
|
|
37）Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999; 55: 2423-32
|
|
|
|
|
|
38）Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002; 62: 1539-49
|
|
|
|
|
|
39）Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006; 1: 19-32
|
|
|
|
|
|
40）Venkatachalam MA, Griffin KA, Lan R, et al. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol. 2010; 298: F1078-94
|
|
|
|
|